Decision Guide · Medical Weight Loss · Utah, Arizona & Idaho
Both are FDA-approved, once-weekly medications that have redefined medical weight loss. One produces larger average results; the other carries the strongest heart-health evidence and usually the friendlier price. Here is how a provider actually decides, and how that decision works for telehealth patients across Utah, Arizona, and Idaho.
Semaglutide activates one receptor (GLP-1); tirzepatide activates two (GLP-1 and GIP). In the first large head-to-head trial, SURMOUNT-5, tirzepatide averaged 20.2 percent body-weight loss versus 13.7 percent for semaglutide over 72 weeks. Tirzepatide wins on average results; semaglutide answers back with dedicated cardiovascular outcome data (the SELECT trial showed roughly 20 percent fewer major cardiac events in adults with obesity and heart disease) and a generally lower market cost. Averages are not individuals: plenty of patients respond beautifully to semaglutide, and the right answer depends on your labs, history, goals, and budget.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Average trial weight loss | About 15 percent at 68 weeks (STEP 1); 13.7 percent in the head-to-head | Up to about 21 percent at 72 weeks (SURMOUNT-1); 20.2 percent in the head-to-head |
| Cardiovascular evidence | SELECT trial: about 20 percent reduction in major cardiac events (obesity + existing heart disease) | Outcome trials ongoing; strong metabolic and insulin-sensitivity data |
| Common side effects | GI effects (nausea, constipation, reflux), mostly during dose increases | Similar GI profile, mostly during dose increases |
| Dosing | Once weekly | Once weekly |
| Typical market cost | Generally lower | Generally higher |
Trial figures are study averages, not guarantees. Vesta prescribes compounded semaglutide and compounded tirzepatide individually through licensed 503A pharmacies after clinical evaluation; your pricing is reviewed with you at consultation, never published as a menu.
Semaglutide tends to lead when heart health is part of the picture (it has the outcome data), when budget matters most, when a gentler entry into GLP-1 therapy makes sense, or when a patient has responded well to it before.
Tirzepatide tends to lead when there is more weight to lose and average results matter, when a patient has plateaued on semaglutide, or when insulin resistance is prominent (the GIP pathway is relevant there).
Switching is routine. The most common move is semaglutide to tirzepatide after a plateau, managed with an appropriate starting dose rather than a unit-for-unit conversion. None of this is decided from a webpage: it is decided from your labs, history, and goals at a consultation.
In the SURMOUNT-5 head-to-head trial, tirzepatide averaged 20.2 percent versus 13.7 percent for semaglutide over 72 weeks. Individual responses vary; some patients do better on semaglutide.
Both are well characterized, with GI effects the most common for each. Semaglutide carries dedicated cardiovascular outcome data from the SELECT trial. The right fit is an individual clinical decision.
Yes, commonly after a plateau. Your provider manages the transition with an appropriate starting dose and monitoring.
Patient-specific 503A compounding, prescribed individually, remains the legal framework Vesta operates under. The landscape is evolving; we keep a plain-English explainer current: is compounded semaglutide legal?
The investigational triple agonist posted even larger trial numbers but is not yet FDA approved. We wrote an honest guide: retatrutide, explained.
Care begins with a $75 initial consultation, where your personalized pricing is reviewed before anything is ordered. Members receive Vesta's most favorable pricing with all consults and follow-ups included. HSA and FSA accepted.
A $75 HIPAA compliant telehealth consultation with Ali Claunch, NP-C settles it, anywhere in Utah, Arizona, or Idaho.
Explore Medical Weight LossFor Utah, Arizona & Idaho patients. Unsubscribe any time.
Questions First?
Prefer to start with a conversation? Ali personally responds to every message within 24 hours.
Meet one-on-one with Ali Claunch, NP-C through a HIPAA compliant telehealth consultation. We review your goals, health history, and labs, then build a personalized treatment plan. Caring for patients across Utah, Arizona, and Idaho, with in-clinic visits in Saratoga Springs.
Ongoing care includes $75 follow-up visits at least every 90 days, so your plan always reflects your progress.
Schedule Your ConsultationA Note on Compounded Medications and FDA Oversight
Compounded peptides, GLP-1 medications, hormone therapies, NAD+ preparations, and other prescription items dispensed through Vesta Aesthetics are prepared by licensed 503A compounding pharmacies for individual patients pursuant to a valid prescription from Ali Claunch, NP-C, following a personalized clinical evaluation. Compounded medications are not FDA-approved. The FDA does not evaluate compounded preparations for safety, efficacy, or potency. Vesta Aesthetics operates in compliance with FDA regulations governing 503A patient-specific compounding and does not stock, resell, or distribute medications outside this framework. If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation.
Information on this site is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary by patient. No specific clinical result is promised or guaranteed. Use of any prescription medication carries risk; please review all risks with your provider before beginning therapy. Vesta Aesthetics is a self-pay medical practice and does not bill insurance. See our 503A Promise for full sourcing detail.